The orally available CCR2/CCR5 inhibitor CVC is currently being evaluated in a phase 2b clinical trial in patients with non-alcoholic steatohepatitis (NASH) and fibrosis [17]. This evidence concerns the gene CCR5 and metabolic dysfunction-associated steatohepatitis.